Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. - Wikidata - awgldk - TriplyDB

Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.

Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.

http://www.wikidata.org/entity/Q46616130

about

Evaluation and management of patients with heart disease and cancer: cardio-oncology Deletion of the β2-adrenergic receptor prevents the development of cardiomyopathy in mice.Predicting adverse side effects of drugs Total beta-adrenoceptor knockout slows conduction and reduces inducible arrhythmias in the mouse heart.Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat.THE ROLE OF β-ADRENERGIC RECEPTORS IN HEART FAILURE: DIFFERENTIAL REGULATION OF CARDIOTOXICITY AND CARDIOPROTECTION.Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy.erbB2 is required for G protein-coupled receptor signaling in the heart.β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways.Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Propranolol enhances cell cycle-related gene expression in pressure overloaded hearts.Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?Selective β2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia-reperfusion injury.Organization of beta-adrenoceptor signaling compartments by sympathetic innervation of cardiac myocytes.Myocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure.Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery.Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis.High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy The association between normal-range admission potassium levels in Israeli patients with acute coronary syndrome and early and late outcomes β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility.High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2 -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts.Compartmentation of cAMP signalling in cardiomyocytes in health and disease.Prevention of Chemotherapy Induced Cardiomyopathy.Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks.β 1 Adrenoceptor antagonistic effects of the supposedly selective β 2 adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts.Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.Myelo-erythroid commitment after burn injury is under β-adrenergic control via MafB regulation.Molecular Changes in Children with Heart Failure Undergoing Left Ventricular Assist Device Therapy.Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.A stress response pathway in mice upregulates somatostatin level and transcription in pancreatic delta cells through Gs and β-arrestin 1.Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure

P2860

Q26998273-57D889A3-5EDB-4A4B-9A2B-735D0C50787F Q30548452-8B0EF804-D379-4C9A-85C5-40D87F42398D Q34173771-84B38A36-75A9-4ECD-AA9A-62CB0097422D Q34469952-32F85FB9-1A1A-42CD-9578-A76EB20C1ED0 Q34498911-2E108AE4-E408-422F-B77D-06891B9CA083 Q34760735-33CA787F-6E9C-49E5-B9BE-785843F52E90 Q35104064-D578CEC0-2459-419C-AD37-627896C8102C Q35117586-EEE24389-48DF-412A-AE93-5B7E415045C0 Q35127519-9B2F1240-FE16-4201-8CED-CE0B766B9CC8 Q35250102-6E69468B-8EAC-41D6-97BC-F7C6EDDE4944 Q35545362-2AB18A26-B253-4913-932B-ADDBFA3DF5F0 Q35635944-B93C1F1E-5838-4085-A794-B8C79C107C79 Q35761448-32B14B37-9CDF-480D-B1B6-484946195E2E Q36106686-1003FC4C-8528-4613-B326-31CFB9A0B603 Q36117806-6A38D7AC-113C-4B82-B412-443D020410DB Q36252791-1F4D129B-F957-4FA5-9E04-20479DA2EAB6 Q36342091-CDA1CBC6-B342-4A81-8357-91A87E33A192 Q36484609-7A975518-C971-4A5D-AEDA-10B94E0E22F3 Q36961294-D42D5933-A5E5-4477-9579-E1337D00D6D8 Q37003646-CAB810DC-F54B-4BE0-917B-E026E68C5AAC Q37201204-54EC5D77-D2EE-4DDF-B6ED-A2700729ACA8 Q37356016-4FE82D43-4E69-4EE7-9400-A1E983183952 Q37700020-34B4589F-E935-477D-B1C3-0C9EABF6A04A Q38079253-BD40E7D4-FED4-4AC5-AD2C-4C7E91C983E6 Q38639587-D00F46F8-12FE-4A3C-B1C4-52B25231E5C4 Q39267607-BC319E0F-F77D-4F3E-9D6C-D40E36203001 Q41808403-8BB5101A-1F29-4D0B-8339-865461BAAE05 Q47098878-6A412B70-5FF3-441E-BD2D-8DFF703D767F Q47358666-AE835379-E5B5-4197-B906-0FE36859ADE6 Q48410009-F58686F8-AF67-4E0C-939D-B300EC6C2549 Q51277742-38E33710-F1BC-4E11-86B1-937E82C3F232 Q54343459-7CE480D8-D921-47D5-B84B-815491B4CCE4 Q57116150-2BA65F71-5399-4891-98F3-311B756CCD98 Q58119331-6979139E-D359-4660-B986-A185EDB5FDB0

P2860

Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.

http://www.wikidata.org/entity/Q46616130

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@en

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@nl

type

label

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@en

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@nl

prefLabel

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@en

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@nl

P1433

Q46616130-51B9E211-6D74-4D98-A679-AB1A64B821FE

P1476

Q46616130-37057255-6744-4629-9AF1-8EC10E2AC4D9

P2093

Q46616130-1D004694-E221-4010-973F-F53052A5F3A0

Q46616130-60437945-AE70-4175-85FB-02243AB1D18C

Q46616130-7684DF91-9056-45BC-968C-A154F8B6F3D5

Q46616130-98BFF8CA-E309-469B-A9F8-20E0FA7116A1

Q46616130-C96865D8-2525-4BF4-B4A3-2A172846F473

Q46616130-E1F12ECC-5526-44BD-8B6C-E0F545530182

P2860

Q46616130-004208FE-93B6-4F56-A39F-B2B686152582

Q46616130-04018A75-FF53-4394-989B-9EA2657617BD

Q46616130-07327420-D824-4BC6-8E51-8302739CC29F

Q46616130-0A8F3FDB-D414-4A40-85F0-23A92DE29B2D

Q46616130-1E19EFD7-ACBE-48B8-8A43-87185285C35C

Q46616130-26227D6E-C3C9-4F8E-B27F-61B3B6E8E760

Q46616130-386EA15A-7546-4DF6-A2BC-17EB3683A1C7

Q46616130-49BDCFFB-6AEF-4B2B-813C-F9044471F277

Q46616130-4A141323-B722-485C-A3CD-92A060DDB659

Q46616130-67846219-7873-491B-8F7F-0BDCB7833340

P304

Q46616130-3E27C716-5EF3-43D2-92D3-1561EE0E97DE

P31

Q46616130-5BD1DA17-D574-4EAE-80C6-F7FBE43636AA

P356

Q46616130-9FE84905-4A0D-4194-B36D-0B770A7E1300

P433

Q46616130-46F9C8F3-378B-41F7-83C7-CA19CF71B0AB

P478

Q46616130-4634D995-EF91-465F-80F2-F68057FE13D3

P50

Q46616130-2056B040-4274-4C7B-83B2-FFD730E687E4

P577

Q46616130-67D2264D-E24E-4AA7-B759-F1FC819334B2

P5875

Q46616130-83CA5778-7E08-4477-9ECF-C7BE2ACA4E51

P698

Q46616130-AD909260-B6F2-4C4B-A4BD-B508E2E2D022

P356

AJPHEART.00005.2005

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Differential cardioprotective/ ...... -adrenergic receptor subtypes.

@en

P2093

Daniel Bernstein

http://www.w3.org/2001/XMLSchema#string

Gerald Berry

http://www.w3.org/2001/XMLSchema#string

Giovanni Fajardo

http://www.w3.org/2001/XMLSchema#string

Jennifer Powers

http://www.w3.org/2001/XMLSchema#string

Mingming Zhao

http://www.w3.org/2001/XMLSchema#string

Takashi Urashima

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of the human beta 3-adrenergic receptor

Cloning of the cDNA for the human beta 1-adrenergic receptor

The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial

Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3

Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

Targeted disruption of the beta2 adrenergic receptor gene

Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects

Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors

P304

H2441-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00005.2005

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

289

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7704251

http://www.w3.org/2001/XMLSchema#string

P698

16040722

http://www.w3.org/2001/XMLSchema#string